Consolidated Financial Result Briefing
for the three months ended June 30, 2023

CYBERDYNE, Inc.
August 14, 2023

FY2023 Q1 Performance highlights
Increase of consolidated revenue +294M (+39%)✅ EU (Italy and Turkey) Increase of rental income from Medical HAL (+36M)✅ Increase of income from treatment service from US. Rise Healthcare Group (+110M)✅ Acquisition of German company LeyLine GmbH (+162M)

Increase of operating loss from 178M to 308M (-130M)✅ Expenses related to the initial investment in setting up a new business in two overseas acquired subsidiaries (twocompanies in the U.S. and Germany) (-127M)

Factor that contributed to recording of pro t before tax : 767M
✅ Gains on valuation differences of investment securities from investments towards startups (868M)✅ Foreign exchange gain from weaker Japanese yen (113M)

fi2

Consolidated nancial results (IFRS)
Year-on-year comparison for the scal year ended March 31, 2023
(Unit: Millions of yen)
FY2022
Q1Revenue(Gross profit)☆

FY2023
Q1+/-+/-%

751

1,045+294 *1+39.1％

(457)

(566)

(+108)(+23.7%)*２-178Operating profit-308-130372767

Treatment Service +110M (Increase of sale from RISE Group in the USA)
Expansion of new business +162M (Acquisition ofGerman Mobility company)*２ Increase in SG&A (254M) (YoY)

ー

*３ *４
Profit before tax*1 Increase in revenue（294M）（YoY）

SG&A expenses of two foreign consolidated subsidiaryacquired through M&A +230M*３ Investment securities 868M (Net) *443M in FY2022 Q1+395+106.2%Finance income (gain on valuation) 246M Gains related to CEJ 623M

*４ Other Exchange loss -113M (+19M YoY)
*５
Profit attributable toowner of the parent

241-88

EBITDA

330-215+89-127+36.9%

ー*5 Income tax 482M (YoY)
Tax effect on valuation gains 392M

☆ Transferred a portion of other SG&A expenses in FY2022 Q1 to cost of sales
due to a review of the cost of sales for treatment services*EBITDA = Operating income + Depreciation and amortization ± Other income and expenses
fifi3

Business performance by type of business : Revenue/ Gross pro t (margin)(Unit: Millions of yen)

Rental of productTreatment service

New business

FY2022Q1FY2023
Q1+/-+/-%388411+22+6%

Operating profit(Margin)170(44%)196(48%)+26+15%

Revenue286

396+110+38%

Operating profit(Margin)-3(-1%)-131(-33%)-129-Revenue

77239+162+210%

Operating profit(Margin)-30(-39%)-85(-36%)-55-

Adjusted
Amount

-316

-288

+28

Revenue

751

1,045

+294

+39%

-178
(-24%)-308(-30%)-130-Revenue

☆

☆

☆

☆☆

Total
☆

Operating profit(Margin)Operating income by business segment is the amount of profit/loss after deducting
operating expenses from revenue by business segment.

☆☆ RD expenses, head office expenses, etc. are adjustments of R&D expenses,
head office administrative expenses, other income and expenses, etc.

• Product rental: Rental income of the Group's products (including some sales)• Treatment services: Income from treatment fees at the Group's treatment facilities (including some service fees at Robocare Centers)• Development of new business areas: Revenue from sales in the Group's new business areas (Mobility subsidiary, Sleep Apps subsidiary, etc.)

4fi

R&D and head office
expensesRental revenue by each products
Rental income Medical Lower Limb Type (overseas) +48M (+61%)(Unit: Millions of yen)

For Hospitals(improving function)

Product classificationJapan

HAL Lower Limb Type(Medical)

83 +1%

127 +61%

209 +30%

Number on the top row：FY2023 Q1

(82)

(79)

(161)

(Number in the brackets in the bottom row) : FY2022 Q1

HAL Lower Limb Type
(Non-medical)

37

HAL Single Joint Type
Well-being

HAL Lumbar Type
HAL Lumbar Type

Labor Support
Mobile Robot (CL02 etc)
Medical Application
Research

Photo-acoustic Imaging(Acoustic X)
OtherTotal

Outside JapanTotal-37

22

2345

(27)

(21)

(47)

252853(38)

(26)

(64)

(45)

11(45)-11-2101919(0)

(17)

(17)

86

14(11)

(7)

(18)

(18)

21(18)(18)(18)

208 -13%203 +35%

411 +6%

(239)

(150)

(388)
5

Consolidated nancial results (IFRS)
by geographical region
Signi cant increase of oversea sale +314M (54% to 69% of total revenue)

Japan 31%

372M

Americas 35%（327M）

Americas 36%

259M

Japan

APAC 9%46%（348M）EMEA 8%

61M

99M

EMEA 24%

84M

247M

APAC 11%
FY2022 Q1

FY2023 Q1Americas: North, Central and South America
EMEA : Europe, the Middle East and Africa
APAC : Asia-Paci c * Revenue from Japan is stated separatelyfififi6Ref) Business performance by type of business and geographical region
Signi cant increase of rental in EMEA, medical service (increase in USA) and new business (EMEA)(Unit: Millions of yen)

FY2023 Q1(FY2022-Q1)

Rental of productTreatment service

New businessTotalJapan

Americas

EMEA

208 -13％

28 +10％76(239)

(25)

(40)

43 +34％344 +47％

9(32)

(234)

(20)

77 -1％(77)-+89％-55％

162(-)

APACTotal

99 +17％411(84)(388)--396+6％+38％(286)239+210％(77)327 -6％372 +44％

247 +308％

99 +17％

1,045 +39％(348)

(259)

(61)

(84)

(751)

fi

7

Development pipeline (1)1) Medical HAL (Lower Limb Type)
Target disease

ProductDevelopment

Clinical Trial(Exploratory)

Clinical Trial(Validation)

As of June 30, 2023

Application/
examination

Approval

Marketing(public healthinsurance in Japan)(Post-marketingsurveillance)

Public healthinsurance

NeuromuscularDisease(8 types of diseasesuch as ALS)

Spastic paraplegia

PublicHealth
Insurance

Approved(Expanded)(HAM etc.)

Spinal Cord Injury

Status
FY2022 revision (DPC calculation)
Public health insurance application
under review (Germany)
Planning for public health insurance
Applied for insurance application
Preparing application for expansion
Preparing application for expansion

Public medicalinsurance
coverage forclinical trials

GermanPublic workers
Compensation
insurance

Discussing with the authorities
Preparing trial for public healthinsurance (Germany)
Planning for public health insurance
Planning additional trial

StrokePlanning for public health insurance
Planning for public health insurance
Investigator-initiated clinical trial

Cerebral Palsy

Multiple Sclerosis
Conducting pilot research8Development pipeline (2)２）Medical HAL (Single Joint Type)
Target disease

ProductDevelopment

Clinical Trial(Exploratory)

Clinical Trial(Validation)

Application/examination

As of June 30, 2023

Approval

Marketing(public healthinsurance in Japan)(Post-marketingsurveillance)

Public healthinsurance
PublicHealth
Insurance

Neurology（e.g. stroke)

StatusAdditional equipment for increased physical activity
Preparing for public health insurance
Preparing for public health insurance

Preparing for public health insurance

Orthopedic

Preparing for public health insurance（e.g. after arti cial kneereplacement)

Preparing for public health insurance３）Medical HAL (Lumbar Type)
Target disease

ProductDevelopment

Clinical Trial(Exploratory)

Clinical Trial(Validation)

As of June 30, 2023

Application/
examination

Approval

Marketing(public healthinsurance in Japan)(Post-marketingsurveillance)

Public healthinsurance

StatusConducting pilot trial

StrokeParkinsons
Disease

Preparing clinical trialfi9Status of approvals by diseases and countries (1)Signi cant progress of legislation process in all regions
1）Medical HAL (Lower Limb Type)
StrokeUSA

Neuromusculardisease*As of March31, 2023

Approved

Approved

Approved

Approved

EUApproved

Approved

Approved

Saudi Arabia

Approved

Approved

Approved

TurkeyThailandApproved
Approved
Approved
Approved

Approved
Approved
Approved
Approved

Taiwan(application in progress)

Singapore

Approved
Approved

Approved
Approved
Approved
Approved
Approved
Approved
Approved

Malaysia
Indonesia
APAC

Spinal Cord Injury(Discussing application method(Following the discussion with thewith the authorities)
authorities, considering additional trials) *Approved for viral (HAM) and hereditary(spastic paraplegia) spinal cord disease.

JapanEMEA

As of June 30, 2023

Australia(application in progress)

Approved
Approved*Spinal muscular atrophy, spinal and bulbar muscular atrophy, amyotrophic lateral sclerosis, Charcot-Marie-Tooth disease, distal muscular dystrophy, inclusion body myositis, congenital myopathy, muscular dystrophy
fi10

Status of approvals by diseases and countries (2)Steady progress in medical devices legislation of Single Joint Type２）Medical HAL (Single Joint Type)EMEANeurology（e.g. stroke）

Orthopedic（e.g. after arti cial knee replacement)

Japan

Certi ed*Certi ed*USA

Approved

ApprovedEU

Approved

Approved

TurkeyApproved

Approved

Saudi Arabia

Approved
Approved
Approved
Approved
Approved
Approved
Approved

Approved
Approved
Approved
Approved
Approved
Approved
Approved

Malaysia
Indonesia
APAC

As of June 30, 2023

ThailandTaiwanSingapore
Australia*As Japanese approval system separates “approvals” and “certi ed”, the term “certi ed” was used for accurate description

fififififi11

Oversea expansion of HAL
Steady progress
in US, EU and APAC
after COVID
HALを使用したNeuro
HALFITを全国展開（全16箇所）
Yellow indicates new introduction areas after After the outbreak of COVID-19
New installation after April 2021
PolandConstance care

Germany*Covered by Public workers
compensation insurance
and private insurance*private insurance
coverage

Italy
Coopselios

EnglandState of Hampshire

California

FranceHospices Civils de Lyon

SerbiaTurkeyDiagenics

Spain
Switzerland

India
IBS Hospital

TaiwanCHC Group Hospital

FloridaBrooks Rehabilitation

Philippines
4 facilities aroundManila

Saudi Arabia
ALJ Hospital

KuwaitSingapore General HospitalThailand

Malaysia
Operated in 10 facilities covered by publicworkers compensation organization

Indonesia

BrazilLarge distribution of HTLV-1associated myelopathy (HAM)
infected individuals
Australia
RoboFit

As of June 30, 2023
12®︎

BioCruces Bizkaia

RISE Healthcare Group(27 facilities)

Disclaimer

This presentation contains forward-looking statements concerning
CYBERDYNE, Inc. and its Group’s future plans, strategies and performance.
Forward-looking statements contained in this presentation are based on
information currently available and on certain assumption redeemed rational at
the time of creation of this presentation. As such, due to various risks anduncertainties, the statements and assumption does not guarantee future
performance, may be considered differently from alternative perspectives andmay differ from the actual result.
Further, this presentation contains statements and information regarding
corporate entities other than those belonging to the CYBERDYNE group, whichhave been complied from various publicly- available sources. CYBERDYNE
does not verify nor guarantees accuracy and appropriateness of those
information.

13